Burrows Scott L sold $2.3M of SYRE
Burrows Scott L (Chief Financial Officer) sold 25,732 shares of Spyre Therapeutics, Inc. (SYRE) at an average of $88.75 ($86.25–$89.35, $2.28M total) across 5 trades over 2026-09-01 to 2026-09-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale provides fresh data on insider holdings, useful for short‑term positioning.
Market read
Primary disclosure of a significant insider sale; modest trading relevance.
What to watch
Potential upcoming clinical data releases could offset sell pressure.
Background
Form 4 filings disclose insider transactions; a CFO sale is noteworthy for traders monitoring insider activity.
Ticker impact
CFO Burrows Scott L sold 25,732 shares for $2.28M via a 10b5‑1 plan, reducing his stake to 79,762 shares.
Modest downward pressure over the next few days.
Large insider sale by CFO, executed through a pre‑arranged plan, suggests possible cashing out; however, the sale size is modest relative to market cap and may be routine.
Market effects
May slightly affect biotech sector sentiment if similar insider sales occur.
Limited to US biotech investors.
Low
Counterpoint
The sale could be a routine liquidity event, not a negative signal.
Key entities
- CompanySpyre Therapeutics, Inc.
Biotech firm developing therapies; ticker SYRE.
- IndividualBurrows Scott L
Chief Financial Officer of Spyre Therapeutics.
